Teva will market the company’s inhalers exclusively in Israel, after signing a marketing and distribution agreement with Syqe® in 2016.

The Pharmacokinetics, Efficacy, Safety, and Ease of Use of the SyqeAir Metered-Dose Cannabis Inhaler for Chronic Neuropathic Pain: A Phase 1a Study
Syqe®’s first study examined whether metered and low doses of Δ9-THC allow for dose-dependent pain reduction of chronic neuropathic pain without significant adverse events. Listen to the podcast>>